Chief Medical Officer · Keros Therapeutics, Inc. (KROS)

Yung Chyung

FY2024 is the first fiscal year CompBrief holds for Yung Chyung as a named executive officer of Keros Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,641,367

Salary $70,615Stock awards $0Bonus $11,320

3rd of 5 named executive officers at Keros Therapeutics by FY2024 total.

5 named officers on file for Keros Therapeutics, FY2024

Yung Chyung’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • KROS’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Keros Therapeutics’s whole pay program stands against its peers

  • Keros Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KROS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2025 (DEF 14A).

Free

Get Yung Chyung’s full pay file as a PDF — free

More than this page: up to 10 years of Yung’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Yung Chyung compensation by year

Keros Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Keros Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$70,615
Bonus$11,320
Stock awards$0
Option awards$5,503,432
Non-equity incentive$56,000
Pension and deferred compensation$0
All other$0
Total$5,641,367

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Keros Therapeutics, Inc. DEF 14A filed April 23, 2025, accession 0001104659-25-037982, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Keros Therapeutics, Inc. filed document, accession 0001104659-25-037982. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option110,000—$67.91

Per the Outstanding Equity Awards at Fiscal Year-End table in Keros Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Keros Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Christopher RovaldiPresident and Chief Operating Officer$6,975,416
Jasbir SeehraChief Executive Officer and Chair$6,273,192
Yung Chyung · this pageChief Medical Officer$5,641,367
Keith RegnanteChief Financial Officer$2,292,177
Simon CooperFormer Chief Medical Officer$1,760,775

The full Keros Therapeutics compensation record

free company brief

This page is one person within Keros Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Keros Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Yung Chyung's compensation dossier · One-time report. No refunds.